Astellas Pharma (ALPMF) Stock Statistics & Valuation Metrics

Astellas Pharma has a market cap or net worth of $30.19B. The enterprise value is $4.36T.

Market Cap

$30.19B

Enterprise Value

$4.36T

Astellas Pharma has 1,809,663,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

1,809,663,100

Owned by Insiders

―

Owned by Institutions

24.16%

Astellas Pharma’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 12.52%.

Return on Equity (ROE)

0.16

Return on Assets (ROA)

0.08

Return on Invested Capital (ROIC)

12.52%

Return on Capital Employed (ROCE)

0.18

Revenue Per Employee

151.73M

Profits Per Employee

20.68M

Employee Count

14,099

Asset Turnover

0.60

Inventory Turnover

1.64

The current PE Ratio of Astellas Pharma is 12.54. Astellas Pharma’s PEG ratio is 0.06.

PE Ratio

12.54

PS Ratio

2.03

PB Ratio

2.45

Price to FCF

9.73

Price to Operating Cash Flow

8.76

PEG Ratio

0.06

In the last 12 months, Astellas Pharma had revenue of 2.14T and earned 291.54B in profits. Earnings per share was 162.77.

Revenue

2.14T

Gross Profit

1.59T

Operating Income

419.70B

Pretax Income

376.59B

Net Income

291.54B

EBITDA

585.25B

Earnings Per Share (EPS)

162.77

In the last 12 months, operating cash flow was 553.53B and capital expenditures -56.18B, giving a free cash flow of 497.35B billion.

Operating Cash Flow

553.53B

Free Cash Flow

497.35B

Free Cash Flow per Share

276.91

Astellas Pharma pays an annual dividend of $0.24, resulting in a dividend yield of 2.88%

Dividend Per Share

$0.24

Dividend Yield

2.88%

Payout Ratio

51.18%

Free Cash Flow Yield

10.28%

Earnings Yield

7.95%

Beta

0.35

52-Week Price Change

48.35%

50-Day Moving Average

15.45

200-Day Moving Average

14.89

Relative Strength Index (RSI)

55.26

Average Volume (3m)

6,757

Astellas Pharma upcoming earnings date is Feb 08, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 04, 2026

Next Earnings Date

Feb 08, 2027

Ex-Dividend Date

Sep 29, 2026

Astellas Pharma as a current ratio of 1.17, with Debt / Equity ratio of 30.91%

Current Ratio

1.17

Quick Ratio

0.90

Debt to Market Cap

0.13

Net Debt to EBITDA

0.49

Interest Coverage Ratio

29.83

In the past 12 months, Astellas Pharma has paid 85.01B in taxes.

Income Tax

85.01B

Effective Tax Rate

0.23

Astellas Pharma EV to EBITDA ratio is 6.79, with an EV/FCF ratio of 10.11.

EV to Sales

2.11

EV to EBITDA

6.79

EV to Free Cash Flow

10.11

EV to Operating Cash Flow

9.08

Astellas Pharma has $238.23B in cash and marketable securities with $424.92B in debt, giving a net cash position of -$186.69B billion.

Cash & Marketable Securities

$238.23B

Total Debt

$424.92B

Net Cash

-$186.69B

Net Cash Per Share

-$103.16

Tangible Book Value Per Share

$340.34

Gross margin is 74.89%, with operating margin of 23.37%, and net profit margin of 16.20%.

Gross Margin

74.89%

Operating Margin

23.37%

Pretax Margin

20.98%

Net Profit Margin

16.20%

EBITDA Margin

31.09%

EBIT Margin

22.74%

The average price target for Astellas Pharma is $15.74, which is 11.43% higher than the current price. The consensus rating is Neutral

Price Target

$15.74

Price Target Upside

9.12% Downside

Analyst Consensus

Neutral

Analyst Count

6

Revenue Growth Forecast

12.25%

EPS Growth Forecast

183.88%